Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolytics Biotech has announced promising interim results from a Phase II study of intravenous Reolysin in patients with sarcomas metastatic to the lung.
Subscribe to our email newsletter
The interim results demonstrate that the treatment has been well tolerated to date, with eight of 16 evaluable patients experiencing stable disease for periods ranging from two to more than 10, 28-day cycles.
As previously announced by Oncolytics, the third patient treated in the study was demonstrated to have stable disease by Recist criteria for more than six months as measured by CT scan. A Pet scan taken at the same time showed that any residual mass was metabolically inert.
Monica Mita, principal investigator of the study said: “Patients have tolerated the treatment well and seem to have disease control up to several months, which is encouraging for patients with advanced refractory sarcoma.”